Biotec Pharmacon at Anglonordic Biotech Conference
(Thomson Reuters ONE) -
CEO Svein Lien is presenting today at the Anglonordic Biotech Conference VIII in
London. Please find further information about the conference
atwww.anglonordicbiotech.com.
Mr. Lien's presentation is available at www.biotec.no.
About Biotec Pharmacon:
Biotec Pharmacon is a Norwegian biopharmaceutical company that develops and
manufactures new immunomodulatory products and cold adapted marine enzymes. The
wholly owned Biotec BetaGlucans AS focuses on new and effective solutions within
wound care, cancer therapies and other immune related disease areas, while
ArcticZymes AS (96% owned) aspires to become a leading supplier of novel enzymes
for diagnostics and genetic research.
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biotec Pharmacon ASA via Thomson Reuters ONE
[HUG#1512778]
Unternehmensinformation / Kurzprofil:
Datum: 05.05.2011 - 11:01 Uhr
Sprache: Deutsch
News-ID 54296
Anzahl Zeichen: 1463
contact information:
Town:
Tromsø
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 144 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biotec Pharmacon at Anglonordic Biotech Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotec Pharmacon ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
